Johnson & Johnson has reached a speedy agreement with a committee of cancer victims to expedite the court appeal regarding their ongoing battle over whether the healthcare giant can use bankruptcy to resolve up to 100,000 talc-related claims. This agreement could potentially cut months off the appeals process, which is significant given the lengthy legal battle these two sides have already endured.
The initial disagreement between Johnson & Johnson and the cancer victims committee resulted in the dismissal of the bankruptcy case filed by LTL Management, a unit set up by the company to address the numerous cancer lawsuits. Normally, appeals of bankruptcy decisions go through a federal district court. However, to streamline the process, both Johnson & Johnson and the committee of cancer victims have requested that the federal appeals court directly take up the matter. US Bankruptcy Judge Michael Kaplan is expected to sign a final order dismissing the bankruptcy case next week, marking the second dismissal.
The cancer lawsuits have remained on hold since Johnson & Johnson first initiated bankruptcy proceedings for LTL back in 2021. However, after the first bankruptcy case was dismissed, the company reached an agreement with tens of thousands of claimants and subsequently put LTL back into bankruptcy, only to have that case dismissed as well. Once the bankruptcy case is officially closed, cancer victims can proceed with pressing for jury trials across the country instead of waiting for a resolution in LTL's Chapter 11 case.
Nevertheless, Johnson & Johnson's appeal is projected to take several months to resolve, even if it is expedited. In January, an appeals court in Philadelphia ordered the dismissal of LTL's initial talc Chapter 11 case after an earlier appeal was fast-tracked. However, this dismissal occurred almost a year after Judge Kaplan rejected the initial attempt by injury claimants to dismiss the company's original talc bankruptcy.
Johnson & Johnson's bankruptcy strategy aimed to persuade cancer victims to drop their claims and accept an $8.9 billion settlement. On the other hand, the victims argue that talc found in baby powder and similar products is contaminated with a toxic substance that contributes to the development of cancer. Johnson & Johnson maintains its stance that their approach seeks fair compensation for injury claimants, many of whom have already lost in court or face waiting years before presenting their cases to a jury. The company continues to deny liability in these lawsuits while asserting the safety of its talc-based products.